OBJECTIVE: To examine the occurrence of arthrogryposis multiplex congenita (AMC) in Europe and to identify possible risk factors. STUDY DESIGN: Retrospective population-based epidemiological study using EUROCAT congenital anomaly registries. The study population included all cases of AMC (based on WHO ICD-9 or ICD-10 codes) that were livebirths (LB), fetal deaths (FD) from 20 weeks gestation and underwent termination of pregnancy for fetal anomaly (TOPFA), 1980-2006. RESULTS: Among 8.9 million births covered by 24 EUROCAT congenital anomaly registries, 757 AMC cases were reported. This gives a prevalence of 8.5 per 100,000. Five hundred and four (67%) AMC cases were LB, 199 (26%) cases were TOPFA, and FD occurred in 54 (7%) cases. First week survival status was known for 381 of the 504 LB (76%), of whom 87 (23%) died within the first week of life. Perinatal mortality associated with AMC was 32%. Two hundred and eighty-two (37%) cases had isolated AMC, 90 (12%) had additional syndrome or chromosomal anomalies and 385 (51%) had other major malformations. The same or similar anomaly was reported in 13% of siblings and in 12% of the mother's own family background. Information on prenatal testing was available for 521 cases of which 360 tested positive for a congenital anomaly, representing a sensitivity of 69%. Information on maternal illness before and during pregnancy and medication use in the first trimester was available for approximately a third of the mothers, of whom the vast majority reported no maternal illness or medication use. CONCLUSION: AMC is a rare occurrence, with a reported prevalence of 1:12,000. In this study, while information on potential risk factors such as maternal disease or maternal use of drugs was limited, they did not appear to be associated with the occurrence of AMC. AMC was lethal in a third of cases, either in utero or during the first week of life, although this may not be solely attributed to AMC as most cases had additional malformations.
OBJECTIVE: To examine the occurrence of arthrogryposis multiplex congenita (AMC) in Europe and to identify possible risk factors. STUDY DESIGN: Retrospective population-based epidemiological study using EUROCAT congenital anomaly registries. The study population included all cases of AMC (based on WHO ICD-9 or ICD-10 codes) that were livebirths (LB), fetal deaths (FD) from 20 weeks gestation and underwent termination of pregnancy for fetal anomaly (TOPFA), 1980-2006. RESULTS: Among 8.9 million births covered by 24 EUROCAT congenital anomaly registries, 757 AMC cases were reported. This gives a prevalence of 8.5 per 100,000. Five hundred and four (67%) AMC cases were LB, 199 (26%) cases were TOPFA, and FD occurred in 54 (7%) cases. First week survival status was known for 381 of the 504 LB (76%), of whom 87 (23%) died within the first week of life. Perinatal mortality associated with AMC was 32%. Two hundred and eighty-two (37%) cases had isolated AMC, 90 (12%) had additional syndrome or chromosomal anomalies and 385 (51%) had other major malformations. The same or similar anomaly was reported in 13% of siblings and in 12% of the mother's own family background. Information on prenatal testing was available for 521 cases of which 360 tested positive for a congenital anomaly, representing a sensitivity of 69%. Information on maternal illness before and during pregnancy and medication use in the first trimester was available for approximately a third of the mothers, of whom the vast majority reported no maternal illness or medication use. CONCLUSION: AMC is a rare occurrence, with a reported prevalence of 1:12,000. In this study, while information on potential risk factors such as maternal disease or maternal use of drugs was limited, they did not appear to be associated with the occurrence of AMC. AMC was lethal in a third of cases, either in utero or during the first week of life, although this may not be solely attributed to AMC as most cases had additional malformations.
Authors: Alexander Conant; Julian Curiel; Amy Pizzino; Parisa Sabetrasekh; Jennifer Murphy; Miriam Bloom; Sarah H Evans; Guy Helman; Ryan J Taft; Cas Simons; Matthew T Whitehead; Steven A Moore; Adeline Vanderver Journal: J Child Neurol Date: 2018-06-08 Impact factor: 1.987
Authors: Hiromi Hirata; Indrajit Nanda; Anne van Riesen; Gai McMichael; Hao Hu; Melanie Hambrock; Marie-Amélie Papon; Ute Fischer; Sylviane Marouillat; Can Ding; Servane Alirol; Melanie Bienek; Sabine Preisler-Adams; Astrid Grimme; Dominik Seelow; Richard Webster; Eric Haan; Alastair MacLennan; Werner Stenzel; Tzu Ying Yap; Alison Gardner; Lam Son Nguyen; Marie Shaw; Nicolas Lebrun; Stefan A Haas; Wolfram Kress; Thomas Haaf; Elke Schellenberger; Jamel Chelly; Géraldine Viot; Lisa G Shaffer; Jill A Rosenfeld; Nancy Kramer; Rena Falk; Dima El-Khechen; Luis F Escobar; Raoul Hennekam; Peter Wieacker; Christoph Hübner; Hans-Hilger Ropers; Jozef Gecz; Markus Schuelke; Frédéric Laumonnier; Vera M Kalscheuer Journal: Am J Hum Genet Date: 2013-04-25 Impact factor: 11.025
Authors: Shenela Lakhani; Ryan Doan; Mariam Almureikhi; Jennifer N Partlow; Muna Al Saffar; Mahmoud F Elsaid; Nada Alaaraj; A James Barkovich; Christopher A Walsh; Tawfeg Ben-Omran Journal: Eur J Med Genet Date: 2017-02-27 Impact factor: 2.708
Authors: Noémi Dahan-Oliel; Sarah Cachecho; Douglas Barnes; Tanya Bedard; Ann M Davison; Klaus Dieterich; Maureen Donohoe; Alicja Fąfara; Reggie Hamdy; Helgi T Hjartarson; Naimisha S Hoffman; Eva Kimber; Igor Komolkin; Ruth Lester; Eva Pontén; Harold J P van Bosse; Judith G Hall Journal: Am J Med Genet C Semin Med Genet Date: 2019-07-07 Impact factor: 3.908
Authors: Alessio Coi; Michele Santoro; Anna Pierini; Judith Rankin; Svetlana V Glinianaia; Joachim Tan; Abigail-Kate Reid; Ester Garne; Maria Loane; Joanne Given; Elisa Ballardini; Clara Cavero-Carbonell; Hermien E K de Walle; Miriam Gatt; Laura García-Villodre; Mika Gissler; Sue Jordan; Sonja Kiuru-Kuhlefelt; Stine Kjaer Urhoj; Kari Klungsøyr; Nathalie Lelong; L Renée Lutke; Amanda J Neville; Makan Rahshenas; Ieuan Scanlon; Diana Wellesley; Joan K Morris Journal: Orphanet J Rare Dis Date: 2022-03-29 Impact factor: 4.123
Authors: José María Vila-Vives; Juan José Hidalgo-Mora; Inmaculada Soler; Juan Rubio; Ramiro Quiroga; Alfredo Perales Journal: Case Rep Obstet Gynecol Date: 2012-11-12